dihydropyridines has been researched along with tamolarizine* in 1 studies
1 other study(ies) available for dihydropyridines and tamolarizine
| Article | Year |
|---|---|
Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist.
A new type of organic Ca2+ channel blocker, tamolarizine, was examined for its reversing effect on multidrug-resistant tumor cells. Tamolarizine synergistically potentiated the cytotoxicity of doxorubicin for doxorubicin-resistant K562 cells (K562/DXR) at a concentration of 0.1-10 microM, but had hardly any synergistic effects in the parental cell line (K562) at the same concentration. Moreover, tamolarizine inhibits the P-glycoprotein pump-efflux activity in a dose-related manner and reduces the expression of the immunoreactive P-glycoprotein in K562/DXR cells as evaluated by cytofluorimetric assay. These results indicate that tamolarizine reverses the multidrug-resistance phenotype through direct interaction with P-glycoprotein. Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Calcium Channel Blockers; Dihydropyridines; Doxorubicin; Drug Resistance, Multiple; Humans; K562 Cells; Piperazines; Rhodamine 123 | 2000 |